Form D · Biotechnology
Apothewell, Inc.
Little Rock, AR · CIK 0001876860
Offering snapshot reported Dec 15, 2023 · SEC filing
- Reported sold
- $11K Offering amount: $200K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $10K Reported outside-investor minimum
- First sale
- Dec 1, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 15, 2023 | Initial | $11,000 | No comparison | 1 | SEC filing |
| Oct 13, 2023 | Initial | $45,000 | No comparison | 9 | SEC filing |
| Mar 28, 2023 | Initial | $40,000 | No comparison | 1 | SEC filing |
| Aug 11, 2022 | Initial | $8,000 | No comparison | 1 | SEC filing |
| Aug 4, 2021 | Initial | $50,000 | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-499817
Offering is in the form of SAFE Agreements, which give the holder the right and option to purchase preferred stock (when issued) using previously paid funds.
Source: Form D, filed Dec 15, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Daniel Sharp | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
417 Main Street
Little Rock, AR, 72201
Little Rock, AR, 72201